<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630938</url>
  </required_header>
  <id_info>
    <org_study_id>17300478</org_study_id>
    <nct_id>NCT04630938</nct_id>
  </id_info>
  <brief_title>Effects of Anaesthesia on Inflammatory Markers</brief_title>
  <official_title>Effects of Anesthetics on Inflammatory Markers in Patients Undergoing Abdominal Surgeries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      undertake confidently both open and laparoscopic cholecystectomy. Major types of body&#xD;
      injuries surgical or accidental; evoke a temporary, yet predictable systemic inflammatory&#xD;
      response caused by hormonal, immunological and metabolic mediators. This inflammatory&#xD;
      response is essential for tissue repair and has evolved to maximize the organisms' healing&#xD;
      potential. In healthy individuals the inflammatory response to major surgery is well balanced&#xD;
      consisting of pro- and anti-inflammatory mediators. The severity of injury, the occurrence of&#xD;
      surgical complications and its accompanying level of stress may hinder the balance of the&#xD;
      inflammatory response6.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue score</measure>
    <time_frame>24 hours</time_frame>
    <description>a scale to measure pain intensity graded from 0 = no pain to 10 = worst pain</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>G-M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-ML</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>intrathecal morphine will be added to anaesthetics</description>
    <arm_group_label>G-M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine+lidocaine</intervention_name>
    <description>local anesthetic will be infused intravenously</description>
    <arm_group_label>G-ML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intravenous saline infusion</description>
    <arm_group_label>G-0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients aging 18 - 55 years old&#xD;
&#xD;
          -  Patients scheduled for abdominal surgeries&#xD;
&#xD;
          -  Patients with American Society of Anesthesiologists (ASA) I, II physical status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients' refusal.&#xD;
&#xD;
          -  Critically ill patients.&#xD;
&#xD;
          -  Patients who have contraindications to regional anesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Esam A. Hamed</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esam A. Hamed, MD</last_name>
      <phone>01002228905</phone>
      <phone_ext>002</phone_ext>
      <email>ehamed@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed F. Mostafa, MD</last_name>
      <phone>01001123062</phone>
      <phone_ext>002</phone_ext>
      <email>mo7_fathy@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Esam Hamed</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

